Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | G6PD | P11413 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21133501 | 0.79 | TP53 (0.55) | ALDH1A1MAPTPOLBRXFP1 | |
| SCHEMBL20161621 | 0.75 | NPC1 (0.42) | ALDH1A1SMN1; SMN2KMT2AAKR1B1MAPT | |
| SCHEMBL21936455 | 0.74 | PORCN (0.51) | MAPT | |
| SCHEMBL21935727 | 0.74 | PORCN (0.58) | — | |
| SCHEMBL21935436 | 0.74 | RAB9A (0.52) | ALDH1A1SMN1; SMN2KMT2AMEN1MAPT | |
| SCHEMBL4539306 | 0.73 | MAPT (0.42) | ALDH1A1SMN1; SMN2KMT2AMEN1MAPT | |
| SCHEMBL21935792 | 0.73 | PDE7A (0.35) | ALDH1A1SMN1; SMN2KMT2AMEN1MAPT | |
| SCHEMBL20079704 | 0.73 | TRPA1 (0.37) | SMN1; SMN2KMT2AMEN1MAPTPOLB | |
| SCHEMBL19036626 | 0.69 | GAA (0.37) | ALDH1A1KMT2ARXFP1 | |
| SCHEMBL12177211 | 0.69 | ALDH1A1 (0.74) | ALDH1A1SMN1; SMN2KMT2AMEN1AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180133170-A1 | METHODS AND COMPOSITIONS FOR TREATING DISORDERS | ELI LILLY AND COMPANY | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180133170-A1 | METHODS AND COMPOSITIONS FOR TREATING DISORDERS | TRPA1, TRPV1, TRPV3 | ALDH1A1 968/4885SMN1; SMN2 129/4885KMT2A 4200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.